Drugs Made In America Acquisition (NASDAQ:DMAA) Shares Down 0.1% – Here’s Why

Shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) fell 0.1% on Friday . The company traded as low as $10.65 and last traded at $10.65. 4,565 shares were traded during trading, a decline of 90% from the average session volume of 46,969 shares. The stock had previously closed at $10.66.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a report on Friday, May 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Drugs Made In America Acquisition Trading Down 0.1%

The stock has a fifty day moving average of $10.61 and a 200-day moving average of $10.51.

Drugs Made In America Acquisition (NASDAQ:DMAA) last released its earnings results on Thursday, May 14th. The company reported $0.06 earnings per share for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Mercuria Capital Strategies LLC bought a new stake in shares of Drugs Made In America Acquisition during the fourth quarter valued at approximately $7,511,000. Boothbay Fund Management LLC purchased a new position in Drugs Made In America Acquisition during the 2nd quarter worth $5,814,000. Radcliffe Capital Management L.P. lifted its holdings in shares of Drugs Made In America Acquisition by 316.7% in the 3rd quarter. Radcliffe Capital Management L.P. now owns 528,100 shares of the company’s stock worth $5,424,000 after buying an additional 401,378 shares during the period. Quarry LP lifted its holdings in shares of Drugs Made In America Acquisition by 1,595.5% in the 4th quarter. Quarry LP now owns 266,551 shares of the company’s stock worth $2,765,000 after buying an additional 250,830 shares during the period. Finally, Governors Lane LP grew its position in shares of Drugs Made In America Acquisition by 2,132.1% during the 4th quarter. Governors Lane LP now owns 250,000 shares of the company’s stock worth $2,594,000 after buying an additional 238,800 shares in the last quarter.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.